Trevi Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 29.07 million compared to USD 29.15 million a year ago. Basic loss per share from continuing operations was USD 0.29 compared to USD 0.45 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.78 USD | +9.45% | -1.94% | +107.46% |
Mar. 20 | Transcript : Trevi Therapeutics, Inc., Q4 2023 Earnings Call, Mar 20, 2024 | |
Mar. 20 | Trevi Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+107.46% | 196M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- TRVI Stock
- News Trevi Therapeutics, Inc.
- Trevi Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023